首页> 外国专利> Effective anticancer drugs against gefitinib-resistant human lung cancer cells comprising the daphnane diterpenoid compound

Effective anticancer drugs against gefitinib-resistant human lung cancer cells comprising the daphnane diterpenoid compound

机译:包含达芙烷二萜类化合物的抗吉非替尼耐药的人肺癌细胞的有效抗癌药

摘要

The present invention relates to a composition that provides an excellent killing effect on the cancer cells represents a useful relates to a drug-resistant cancer cells to anticancer agents, in particular resistant to conventional anti-cancer agent containing the compound separated from the won extract as an active ingredient. In particular, the present invention of the composition is epidermal growth factor receptor (Epithelial Growth Factor Receptor, EGFR) inhibitor, the error correcting capability of the nip (Gefitinib) anticancer drugs resistant to represent cells in the visible cancer drug resistance to overcome to be in normal cancer cells, as well as anticancer agent resistance for indicating because cells in the antitumor effect, can be used as a pharmaceutically useful anti-cancer agents. ;
机译:本发明涉及对癌细胞具有优异的杀伤作用的组合物,该组合物涉及对抗癌药具有耐药性的癌细胞,特别是对含有从the提取物中分离的化合物的常规抗癌药具有抗性的组合物。活性成分。特别地,本发明的组合物是表皮生长因子受体(Epithelial Growth Factor Receptor,EGFR)抑制剂,其对nip(吉非替尼)抗癌药的纠错能力代表细胞在可见癌中的耐药性,克服了在正常癌细胞中,还有抗癌药的抗药性,因为细胞具有抗肿瘤作用,因此可以用作药学上有用的抗癌药。 ;

著录项

  • 公开/公告号KR101388635B1

    专利类型

  • 公开/公告日2014-04-25

    原文格式PDF

  • 申请/专利权人

    申请/专利号KR20120081011

  • 申请日2012-07-25

  • 分类号A61K31/36;A61K31/336;A61P35/00;

  • 国家 KR

  • 入库时间 2022-08-21 15:41:03

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号